New inhaled therapy for lung blood pressure passes first safety hurdle
Disease control
Recruiting now
This early-stage trial tests the safety of a single inhaled dose of L608 in 32 healthy volunteers. L608 is a liposomal formulation designed to treat pulmonary arterial hypertension, a condition of high blood pressure in the lungs. The study compares different doses against a plac…
Phase: PHASE1 • Sponsor: Pharmosa Biopharm Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC